Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 8/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 6/20 | 0.38 |
| ▸ | JAK2 | O60674 | 3/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | BCHE | P06276 | 1/20 | 0.30 |
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18907393 | 0.84 | JAK2 (0.31) | JAK2 | |
| SCHEMBL18907252 | 0.75 | ESR1 (0.44) | ESR1ESR2LMNAKDM4ESMN1; SMN2 | |
| SCHEMBL18907184 | 0.72 | ESR1 (0.49) | ESR1ESR2LMNAKDM4ESMN1; SMN2 | |
| SCHEMBL18907303 | 0.72 | ESR1 (0.43) | ESR1ESR2LMNAKDM4ESMN1; SMN2 | |
| SCHEMBL18907191 | 0.71 | MEN1 (0.44) | ESR1ESR2LMNAKDM4ESMN1; SMN2 | |
| SCHEMBL18907270 | 0.71 | ESR1 (0.49) | ESR1ESR2LMNAKDM4ESMN1; SMN2 | |
| SCHEMBL18907262 | 0.69 | MEN1 (0.31) | MEN1MAPTKMT2A | |
| SCHEMBL18907300 | 0.69 | ESR1 (0.44) | ESR1ESR2KDM4ESMN1; SMN2MAPT | |
| SCHEMBL18907275 | 0.68 | ESR1 (0.43) | ESR1ESR2LMNAKDM4ESMN1; SMN2 | |
| SCHEMBL18907359 | 0.68 | ESR1 (0.46) | ESR1ESR2LMNAKDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170155057-A1 | CONDENSED CYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | SAMSUNG DISPLAY CO., LTD. (KR) | 2017-06-01 | — | — | US | disclosed |
| US-20170155057-A1 | CONDENSED CYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | SAMSUNG DISPLAY CO., LTD. (KR) | 2017-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170155057-A1 | CONDENSED CYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | CRY1, OCIAD1, CCNT1 | ESR1 114/4885ESR2 456/4885JAK2 4514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.